Form 4: ResMed CFO Brett Sandercock Sells 1,000 Shares Under 10b5-1 Plan

ResMed's Chief Financial Officer, Brett Sandercock, sold 1,000 shares of ResMed common stock at a price of $209.81 per share on June 10, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On June 10, 2024, Brett Sandercock, the Chief Financial Officer of ResMed Inc., sold 1,000 shares of ResMed common stock.
• The sale was executed at a price of $209.81 per share.
• The transaction was conducted under a Rule 10b5-1 plan adopted on February 6, 2024.
• Following the transaction, Sandercock directly owns 91,056 shares of ResMed common stock, which includes 94.177 shares purchased on April 30, 2024, through the ResMed Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The sale was conducted under a pre-arranged 10b5-1 trading plan, which mitigates any negative interpretation. The CFO still holds a significant number of shares.

Industry Context

Insider transactions are routinely monitored by investors to gauge executive sentiment regarding the company's prospects. Sales under a 10b5-1 plan are less indicative of current sentiment, as these plans are pre-arranged.

Stakeholder Impact

• The sale of shares by a high-ranking executive could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates